AlgoTx
Biotechnology ResearchÎle-de-France, France11-50 Employees
AlgoTherapeutix (AlgoTx) is a clinical stage biotechnology company developing targeted, first in class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is based on a topical reformulation of amitriptyline with two lead indications of high unmet need that lead to unbearable pain in patient’s extremities and for which there are currently no viable treatment options. ATX01 targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. Its topical administration provides targeted pain relief from the excruciating pain in patient’s extremities for its two lead indications; CIPN, caused by nerve degeneration and a common side effect of cancer treatment, and EM, a rare disease characterized by painful extremities. In CIPN, the company is recruiting into a Phase II clinical trial of up to 240 patients (the ‘ACT’ study). This trial is due to provide its final data read out in H2 2024, and the company is making plans to expedite a Phase 3 trial. In EM, the company is recruiting up to 14 patients into a Phase II proof of concept trial (the ‘EASE’ study). The trial is due to read out in H1 2024 and has company has secured FDA & EMA fast track development and orphan drug status. The company has seasoned leadership, with experience of bringing global products successfully to market, and is backed by an international board. AlgoTx raised a Series B round of EUR 20 million in 2022 and has raised EUR 35 million to date. AlgoTx has a consortium of investors including Relyens Innovation Santé / Turenne Capital, who led the Series B fund raise, along with UI Investissement, and angel investors. Historical investors include Bpifrance through its Innobio 2 fund and Omnes Capital. In 2023, the company won France Biotech’s prestigious ESG HealthTech Trophy in recognition of its early commitment to ESG initiatives. For more information, see the company’s website
1-888-653-2347 
support@leadiq.com 
